RAD001 (Everolimus)
RAD001 (Everolimus) is a pharmaceutical drug with 9 clinical trials. Currently 1 active trials ongoing. Historical success rate of 85.7%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
85.7%
6 of 7 finished
14.3%
1 ended early
1
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Clinical Trials (9)
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9